[Federal Register: June 1, 2004 (Volume 69, Number 105)]
[Notices]
[Page 30945]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01jn04-109]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D-0042]
Draft Guidances for Industry on Improving Information About
Medical Products and Health Conditions; Availability; Reopening of
Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; reopening of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is reopening until
August 10, 2004, the comment period for the draft guidances entitled
``Brief Summary: Disclosing Risk Information in Consumer-Directed Print
Advertisements,'' ``Help-Seeking and Other Disease Awareness
Communications by or on Behalf of Drug and Device Firms,'' and
``Consumer-Directed Broadcast Advertising of Restricted Devices.'' FDA
published a notice of availability of the draft guidances in the
Federal Register of February 10, 2004 (69 FR 6308). FDA is taking this
action in response to requests for an extension and to allow interested
parties additional time to submit comments.
DATES: Submit written or electronic comments on the draft guidances by
August 10, 2004. General comments on agency guidance documents are
welcome at any time.
ADDRESSES: Submit written requests for single copies of the draft
guidances to the Division of Drug Information (HFD-240), Center for
Drug Evaluation and Research, Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857; or to the Office of Communication,
Training, and Manufacturers Assistance (HFM-40), Center for Biologics
Evaluation and Research, Food and Drug Administration, 1401 Rockville
Pike, Rockville, MD 20852-1448. Send one self-addressed adhesive label
to assist that office in processing your requests. Submit written
comments on the draft guidances to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. See the SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance documents.
FOR FURTHER INFORMATION CONTACT:
Regarding prescription human drugs: Lesley R. Frank, Center for
Drug Evaluation and Research (HFD-42), Food and Drug Administration,
5600 Fishers Lane, Rockville, MD 20857, 301-827-2831.
Regarding prescription human biological products: Glenn N. Byrd,
Center for Biologics Evaluation and Research (HFM-600), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-
3028.
Regarding medical device products: Deborah Wolf, Center for Devices
and Radiological Health (HFZ-300), 2098 Gaither Rd., Rockville, MD
20850, 301-594-4589.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of February 10, 2004 (69 FR 6308), FDA
published a document announcing the availability of three draft
guidance documents entitled ``Brief Summary: Disclosing Risk
Information in Consumer-Directed Print Advertisements,'' ``Help-Seeking
and Other Disease Awareness Communications by or on Behalf of Drug and
Device Firms,'' and ``Consumer-Directed Broadcast Advertising of
Restricted Devices.'' The draft guidances are intended to provide clear
advice to medical product firms on how to fulfill the requirements in
FDA's rules applicable to certain communications to consumers and
health care professionals.
In the February 2004 notice of availability, FDA specifically
requested comments on a number of issues addressed in the draft
guidances. The agency also requested submission of research and data
related to these issues. The initial comment period closed on May 10,
2004. FDA received a request dated April 2, 2004, and numerous requests
dated May 8, 2004, that the agency extend the comment period. The
requests cite the need for additional time because of the importance of
the subject matter to be commented on. The requests also state an
extension is needed for consultation with interested parties, to
complete research, and to prepare comments. In response to these
requests, FDA has decided to reopen the comment period until August 10,
2004.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written comments on the draft guidance documents by
August 10, 2004. Two copies of any comments are to be submitted, except
that individuals may submit one copy. Comments should be identified
with the docket number found in brackets in the heading of this
document. Comments should identify clearly which guidance they are
commenting on. The draft guidance documents and received comments may
be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday.
III. Electronic Access
Copies of the draft guidances are available on the Internet at
http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/cder/guidance/index.htm, http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/cber/guidelines, or http://ww.fda.gov/ohrms/dockets/default.htm.
lt.htm.
Dated: May 25, 2004.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 04-12270 Filed 5-28-04; 8:45 am]
BILLING CODE 4160-01-S